England

Not intended for UK-based media First publication of primary analysis shows robust and durable clinical response in patients with advanced non-small cell lung cancer (NSCLC) with MET exon14 (METex14) skipping alterations; data also presented during ASCO 2020 Meaningful clinical benefit was shown to be consistent across different lines of treatment with or without brain metastases, […]